Contribution of the immune system to the chemotherapeutic response.
about
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyMito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical modelTumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast CancerDexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies.Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.Immunological off-target effects of standard treatments in gastrointestinal cancersPrognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.Restoration of defective cross-presentation in tumors by gemcitabine.Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapyTranscatheter Arterial Chemoembolization Combined with Simultaneous Computed Tomography-guided Radiofrequency Ablation for Large Hepatocellular Carcinomas.Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells.A Systems Biology Approach Provides Deeper Insights into Differentially Expressed Genes in Taxane-Anthracycline Chemoresistant and Non-Resistant Breast CancersCirculating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.
P2860
Q26825053-90381A41-AE63-4280-8423-B17B35CB75F8Q27310238-5133573F-6D9E-4FB0-914F-30048C122534Q35149726-7360AAAB-9733-4949-AC48-6BC91C85A3D1Q36821113-F43C8BAE-B072-4DA7-94A1-36C26479A352Q36946100-0FCF4C07-0581-4EE9-804F-7BB9C253D5FCQ37404086-61BF84D8-F10D-4FE5-9067-2A9FD548FB60Q37745995-EC25466B-3BF6-4C46-B99A-AB0C5B018453Q37746144-12F86B27-329A-4CBF-A1B6-6AB68BF280A9Q38971333-DF58A62F-42DA-4B24-BB02-6EC94478C7FFQ41592003-69F79E95-F4A5-44A6-914D-1DD13A4F1F5AQ42180889-75627DDE-8935-4FD0-9F15-C52977688981Q47132622-76C0ED6B-7D83-4FC5-81D9-AC0281B7B1A5Q47241875-5F9927A3-9779-452E-B6F1-2B6102E3C68CQ47601795-B64A54C8-DB03-4043-B485-05DD366FC6CDQ50901950-C47868A2-4A8F-4D59-835A-AA5240B0386F
P2860
Contribution of the immune system to the chemotherapeutic response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Contribution of the immune system to the chemotherapeutic response.
@en
Contribution of the immune system to the chemotherapeutic response.
@nl
type
label
Contribution of the immune system to the chemotherapeutic response.
@en
Contribution of the immune system to the chemotherapeutic response.
@nl
prefLabel
Contribution of the immune system to the chemotherapeutic response.
@en
Contribution of the immune system to the chemotherapeutic response.
@nl
P2860
P1476
Contribution of the immune system to the chemotherapeutic response
@en
P2093
Richard A Lake
P2860
P2888
P304
P356
10.1007/S00281-011-0246-Z
P577
2011-01-28T00:00:00Z